Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development

The empirical hypothesis generation and testing approach to pharmaceutical research and development (R&D), and biomedical research has proven very effective over the last half-century; resulting in tremendous increases productivity and the rates of approval for new drug applications at the Food and Drug Administration (FDA). However, as discovery of new therapeutic approaches for diseases with unmet medical need becomes more challenging, the productivity and efficiency of the traditional approach to drug discovery and development is diminishing. Innovative approaches are needed, such as those offered by Quantitative Systems Pharmacology (QSP) modeling and simulation. This “systems” approach to modeling and simulation can be used to guide the hypothesis generation and testing process in pharmaceutical R&D, in a manner similar to its adoption in other industries in the past. Embedding QSP into the existing processes within pharmaceutical discovery and development will be required in order to realize the full beneficial impact of this innovative approach.

[1]  A. De Pasquale Pharmacognosy: the oldest modern science. , 1984, Journal of ethnopharmacology.

[2]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008 .

[3]  K Gadkar,et al.  The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non‐obese diabetic mouse , 2010, Clinical and experimental immunology.

[4]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[5]  Oleg Demin,et al.  Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.

[6]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[7]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  H. Geerts,et al.  A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease , 2013, Front. Pharmacol..

[9]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[10]  H Geerts,et al.  A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia , 2013, CPT: pharmacometrics & systems pharmacology.

[11]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[12]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[13]  R. Pluta,et al.  Quantitative Systems Pharmacology Model of NO Metabolome and Methemoglobin Following Long-Term Infusion of Sodium Nitrite in Humans , 2013, CPT: pharmacometrics & systems pharmacology.

[14]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[15]  A. Pasquale Pharmacognosy: the oldest modern science. , 1984, Journal of ethnopharmacology.

[16]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[17]  J. Drews Drug discovery: a historical perspective. , 2000, Science.

[18]  Walter S. Woltosz If we designed airplanes like we design drugs… , 2011, Journal of Computer-Aided Molecular Design.

[19]  J. J. Jehring The productivity crisis , 1967 .

[20]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[21]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[22]  M. Danhof,et al.  First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development , 2012, Journal of Pharmacokinetics and Pharmacodynamics.